2 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Daniela Matei, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembro/Carbo/Taxol in Endometrial Cancer Pembrolizumab, Paclitaxel, Carboplatin - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Completed | Daniela Matei, MD | 46 | 2017-08-22 | 2022-03-02 |
| Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer Sorafenib, Topotecan - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Daniela Matei, MD | 30 | 2007-09-01 | 2016-03-03 |
| Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer Imatinib Mesylate, Docetaxel - Ovarian Cancer | Phase 2 | Completed | Daniela Matei, MD | 23 | 2003-12-01 | 2016-02-19 |
Ovarian Neoplasms (2) · Endometrial Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Carboplatin (1) · Docetaxel (1) · Imatinib Mesylate (1) · Paclitaxel (1) · Sorafenib (1) · Topotecan (1) · pembrolizumab (1)
United States (3)